On The Pen: The Weekly Dose +
Help us continue making great content for listeners everywhere.
Support
Starting at $3/month
On The Pen: The Weekly Dose
Dave Knapp Man On The Mounjaro
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
On The Pen: The Weekly Dose 7.23.24July 22, 2024
On The Pen: The Weekly Dose 7.16.24July 15, 2024
Amylin and the future of obesity medicine with Dr. Beverly TchangJuly 12, 2024
.png)
On The Pen: The Weekly Dose 7.9.24July 08, 2024
On The Pen: The Weekly Dose 7.2.24July 02, 2024
On The Pen: The Weekly Dose 6.25.24June 25, 2024
On The Pen: The Weekly Dose 6.18.24June 18, 2024
Zepbound And Liver DiseaseJune 12, 2024
On The Pen: The Weekly Dose 6.11.24June 10, 2024
On The Pen: The Weekly Dose 6.4.24June 04, 2024
OTP EPS 68: Ro CEO Zach Reitano Talks GLP-1 Supply TrackerMay 31, 2024
.jpeg)
On The Pen: The Weekly Dose 5.28.24May 28, 2024
On The Pen Live Eps 67: Survodutide Trial Participant Tells All!May 25, 2024
On The Pen: The Weekly Dose 5.21.24May 20, 2024
On The Pen: The Weekly Dose 5.14.24May 13, 2024
Threats to Lilly's Zepbound & Mounjaro Printing PressMay 11, 2024
On The Pen: The Weekly Dose 5.7.24May 08, 2024
Lilly Earnings Call: Zepbound and Mounjaro Updates April 30, 2024
On The Pen: The Weekly Dose 4/30/24April 29, 2024
On The Pen: The Weekly Dose 4/23/24April 23, 2024
Zepbound Vials: The Business Case April 19, 2024
On The Pen: The Weekly Dose 4/16/24April 15, 2024
Sourcing Compound Tirzepatide April 13, 2024
On The Pen: The Weekly Dose 4.9.24April 08, 2024
Zepbound Single Dose Vials Approved!April 01, 2024
